Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.
Clin Immunol
; 214: 108382, 2020 05.
Article
in En
| MEDLINE
| ID: mdl-32169439
ABSTRACT
With the successful treatment of B-cell lymphomas using rituximab, a monoclonal antibody targeting CD20, novel immunotherapies have developed rapidly in recent years. Immune checkpoint blockade and chimeric antigen receptor-T (CAR-T) cell therapy, which are antibody-based therapy and cell-based therapy, respectively, show promising efficacy and have been approved by the Food and Drug Administration for treating hematological malignancies. However, considering severe side effects and short-term clinical remission, the combination of CAR-T cell therapy and programmed cell-death protein-1 (PD-1) blockade has been applied to enhance therapeutic efficacy in preclinical models and clinical trials. Herein, we review the mechanism of the two therapies, show their toxicities and clinical use respectively, address their combined application, and discuss the scope of further investigations of this mechanism-based combination therapy.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Immunotherapy, Adoptive
/
Lymphoma, B-Cell
/
Hematologic Neoplasms
/
Molecular Targeted Therapy
/
Programmed Cell Death 1 Receptor
/
Neoplasm Proteins
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Clin Immunol
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2020
Type:
Article
Affiliation country:
China